Comparative Study Between Oxytocin Infusion Before and After Placental Delivery on Blood Loss During and After Cesarean Delivery .

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-30

Study Completion Date

2024-09-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Participants were randomized using computer-generated random numbers into 2 groups. Group I included 32 women who received oxytocin infusion before placental delivery just after cord clamping and group II included 32 women who received oxytocin infusion after placental delivery. In both groups 10 IU of oxytocin (Syntocinon, Novartis, Basel, Switzerland) were diluted in 500 mL of normal saline and administered through intravenous infusion over 30 minutes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oxytocin to Decrease Blood Loss During Cesarean Section

NCT00891150

Complications; Cesarean Section

COMPLETED NA

Oxytocin Dosing at Planned Cesarean Section and Anemia

NCT03361124

Blood Loss Anemia Uterine Atony With Hemorrhage

WITHDRAWN PHASE4

Oxytocin Infusions and Blood Loss in Patients Undergoing Elective Cesarean Delivery.

NCT01932060

Postpartum Hemorrhage

COMPLETED PHASE3

A Randomized Trial Comparing Oxytocin and Oxytocin + Ergometrine for Prevention of Postpartum Haemorrhage at Caesarean Section

NCT02046499

Prevention of Post Partum Haemorrhage

COMPLETED NA

Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With PASD Undergoing Cesarean Hysterectomy

NCT06493968

Placenta Accreta Spectrum

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants were randomized using computer-generated random numbers into 2 groups. Group I included 32 women who received oxytocin infusion before placental delivery just after cord clamping and group II included 32 women who received oxytocin infusion after placental delivery. In both groups 10 IU of oxytocin (Syntocinon, Novartis, Basel, Switzerland) were diluted in 500 mL of normal saline and administered through intravenous infusion over 30 minutes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intraoperative Blood Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

oxytocin before placental delivery

oxytocin infusion before placental delivery just after cord clamping 10 IU of oxytocin (Syntocinon, Novartis, Basel, Switzerland) were diluted in 500 mL of normal saline and administered through intravenous infusion over 30 minutes.

Group Type ACTIVE_COMPARATOR

Oxytocin

Intervention Type DRUG

10 IU of oxytocin (Syntocinon, Novartis, Basel, Switzerland) were diluted in 500 mL of normal saline and administered through intravenous infusion over 30 minutes.

oxytocin after placental delivery

oxytocin infusion after placental delivery 10 IU of oxytocin (Syntocinon, Novartis, Basel, Switzerland) were diluted in 500 mL of normal saline and administered through intravenous infusion over 30 minutes.

Group Type ACTIVE_COMPARATOR

Oxytocin

Intervention Type DRUG

10 IU of oxytocin (Syntocinon, Novartis, Basel, Switzerland) were diluted in 500 mL of normal saline and administered through intravenous infusion over 30 minutes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oxytocin

10 IU of oxytocin (Syntocinon, Novartis, Basel, Switzerland) were diluted in 500 mL of normal saline and administered through intravenous infusion over 30 minutes.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 - 40 years
* singleton full term pregnancy.
* Candidate for elective cesarean delivery under spinal anaesthesia

Exclusion Criteria

* women at high risk for intraoperative bleeding as those with placenta previa or other placental abnormalities
* women with bleeding or coagulation disorders.
* Medical disorder associating pregnancy as preeclampsia or diabetes
* Allergy or contraindications to oxytocin
* Fetal macrosomia, or congenital anomalies
* Polyhydramnios
* Uterine abnormalities as fibroids
* Women with intraoperative complications as vascular or visceral injuries

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No